Pharming Group N.V.
Research Pharming Group N.V. (PHAR) on Bullrun: market cap USD 833.06M, P/E 94.7. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPHAR
- ExchangeNASDAQ
- CountryNetherlands
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 833.06M
- P/E94.7
- Financial periodQ2 2026
- RevenueUSD 90.21M
- Net incomeUSD 1.64M
- Free cash flow-USD 9.74M
- Gross margin83.9%
Valuation Snapshot
latest market cap is USD 833.06M; P/E is 94.7.
Peer valuation comparison
Latest P/E is 94.69x versus a Healthcare sector median of 24.46x (287.1% above).
Latest P/E is 94.69x versus a Netherlands median of 18.23x (419.4% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 106.77B | USD 5.30B | USD 53.95M | 80.2% | -0.29 | USD 145.31M | USD 115.78M | USD 277.10M |
| FY2024 | USD 92.90B | USD 2.89B | -USD 2.59M | 86.8% | -0.36 | USD 54.94M | USD 112.31M | USD 221.06M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 833.06M | 94.7 | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.21B | 589.0 | n/a | n/a |
| 2024 | 2024-12-31 | USD 684.39M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 753.44M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 719.61M | 25.7 | n/a | n/a |
| 2021 | 2021-12-31 | USD 579.98M | 35.8 | n/a | n/a |
About Pharming Group N.V.
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE);
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Pharming Group N.V.'s market cap?
Pharming Group N.V.'s market capitalization is USD 833.06M.
What is Pharming Group N.V.'s P/E ratio?
Pharming Group N.V.'s price-to-earnings (P/E) ratio is 94.7.
What does Pharming Group N.V. do?
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K?